Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.45 |
| ▸ | SELE | P16581 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187294 | 0.87 | PARP10 (0.55) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL21628562 | 0.87 | PARP10 (0.55) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL3024115 | 0.85 | PARP10 (0.67) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL21628476 | 0.85 | OPRK1 (0.53) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL27245278 | 0.84 | PARP10 (0.62) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL21628641 | 0.83 | S1PR1 (0.55) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL21628730 | 0.82 | PARP10 (0.59) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL26214383 | 0.82 | PARP10 (0.63) | PARP10OPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL30289581 | 0.82 | PARP10 (0.67) | PARP10OPRK1OPRM1OPRD1PARP15 | |
| SCHEMBL21628639 | 0.82 | S1PR1 (0.52) | PARP10OPRK1OPRM1OPRD1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3544972-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | Pfizer Inc (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | ATIC, ADORA1, ADORA2A | PARP10 4198/4885OPRK1 1387/4885OPRM1 1523/4885 |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | PARP10 1704/4885OPRK1 1/4885OPRM1 3/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | PARP10 1704/4885OPRK1 1/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.